Brief: Vertex Announces Progress In Povetacicept Development Program And Presentation Of New Data At American Society Of Nephrology Kidney Week
17/10/2025 14:08
Oct 17 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES PROGRESS IN POVETACICEPT DEVELOPMENT PROGRAM AND PRESENTATION OF NEW DATA AT AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK VERTEX PHARMACEUTICALS INC - FDA GRANTS ROLLING REVIEW FOR POVETACICEPT IN IGA NEPHROPATHY VERTEX PHARMACEUTICALS INC: EXPECTS TO SUBMIT FIRST MODULE TO FDA FOR POTENTIAL ACCELERATED APPROVAL BEFORE END OF 2025 VERTEX PHARMACEUTICALS INC: REMAINS ON TRACK TO COMPLETE FULL BLA SUBMISSION FOR ACCELERATED APPROVAL IN U.S. IN FIRST HALF OF 2026 Source text: ID:nBw3Hntz4a Further company coverage: VRTX.O
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31